InterVenn

High-Level Overview

InterVenn Biosciences is a biotechnology company pioneering clinical glycoproteomics through its AI-powered GlycoVision™ platform, which decodes the human glycoproteome—glycosylated proteins driving biological functions—to advance personalized medicine, biomarker discovery, and diagnostics.[1][2] The platform serves physicians, researchers, and biopharma organizations by enabling high-throughput analysis of intact glycopeptides via liquid chromatography-tandem mass spectrometry (LC-MS/MS), solving longstanding challenges in manual data interpretation and unlocking insights for cancer detection, treatment response, and disease monitoring.[1][2][3] Key products like VISTA™ and Peak Integration Platform (PIP) provide the first commercially available tools for site-specific protein glycosylation assessment in serum or plasma, with applications in oncology and precision medicine, backed by clinical evidence in journals like Gastroenterology and Journal of Hematology & Oncology.[2][4][5]

Origin Story

Founded in 2017, InterVenn emerged from a collaboration among Nobel Laureate Dr. Carolyn Bertozzi (known for her work in bioorthogonal chemistry), distinguished glycobiology professor Dr. Carlito Lebrilla, and AI/ML expert Aldo Carrascoso, uniting expertise in chemistry, biology, and artificial intelligence to tackle glycoproteomics.[1] The idea stemmed from recognizing glycoproteins as an untapped layer of biology for drug development and patient outcomes, with early innovation in AI to automate LC-MS/MS chromatogram analysis—previously manual and error-prone—achieving over 99% concordance to expert reviews.[1][3] Pivotal moments include securing investment from Anzu Partners in July 2020 and presenting "Poster of Distinction" data at Digestive Disease Week 2023 on pre-cancer detection via serum glycoproteins.[4]

Core Differentiators

• AI-ML Integration with LC-MS/MS: Proprietary workflow combines high-performance liquid chromatography-mass spectrometry with neural networks for automated, quantitative glycopeptide analysis, eliminating manual annotation and handling thousands of chromatograms per sample with high accuracy.[1][3]
• GlycoVision™ and VISTA™ Platforms: First tools for intact glycopeptide quantification and site-specific glycosylation profiling in clinical samples, enabling biomarker discovery for disease detection, progression, and therapy response—overcoming traditional glycoproteomics barriers like poor reproducibility.[2][3][4][5]
• Peak Integration Platform (PIP): AI-driven software using recurrent neural networks, trained on expert-annotated data, to convert complex LC-MS outputs into interpretable biomarkers with robustness and interpretability, avoiding "black box" predictions.[3]
• Clinical Validation and Partnerships: Robust pipeline with peer-reviewed evidence (e.g., early adenoma detection, PD-1 glycosylation in immunotherapy) positions it as a key partner for biopharma R&D and diagnostics.[1][2][4]

Role in the Broader Tech Landscape

InterVenn rides the precision medicine wave, targeting the glycoproteome—a "new frontier" for biomarkers in cancer and beyond—amid rising demand for liquid biopsies that offer non-invasive, high-resolution insights over genomics or proteomics alone.[2] Timing aligns with AI advancements in biotech signal processing and mass spectrometry evolution, amplified by post-2020 investments and Nobel-recognized glycobiology breakthroughs, fueling oncology applications like early detection and immune checkpoint modulation.[1][3][4] Market forces include biopharma's push for better therapeutics (e.g., glycosylation's role in protein function) and regulatory interest in validated diagnostics; InterVenn influences the ecosystem by commercializing tools like VISTA™, enabling partners to accelerate R&D and expand glycoproteomics from research to clinic.[2][4][5]

Quick Take & Future Outlook

InterVenn is poised to scale its GlycoVision™ platform into broader diagnostics and therapeutic partnerships, leveraging clinical validations to target high-value oncology indications and beyond.[2][4] Trends like AI-biotech convergence, liquid biopsy growth, and glycosylation's emerging role in immunotherapy will propel expansion, potentially evolving it into a standard for precision medicine workflows. As a portfolio company backed by strategic investors, its influence could amplify through licensed panels and collaborations, transforming biomarker discovery from niche to mainstream. This positions InterVenn at the vanguard of decoding biology's "hidden layer" for better patient outcomes.[1][2]